Paper describes Affiris' PCSK9 vaccine's efficacy
In a paper published in the European Heart Journal, researchers at Affiris AG (Vienna, Austria) showed a vaccine against PCSK9 reduced cholesterol levels and atherosclerosis in mice.
The vaccine, AT04A, consisted of a peptide mimic of a portion of the PCSK9 protein conjugated to an immunogenic carrier. In a mouse model of atherosclerosis, AT04A lowered total cholesterol by 53%, decreased atherosclerotic lesions and plaques, and decreased vascular inflammation 18 weeks after immunization compared with no vaccine. AT04A also elicited antibodies against PCSK9 and decreased PCSK9 plasma concentrations...
BCIQ Company Profiles
BCIQ Target Profiles